课题基金 / 基金详情

项目摘要

项目成果

QIANG DING的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 特发性肺纤维化(IPF)是一种慢性肺部疾病,导致进行性呼吸功能不全和肺纤维化,最终导致死亡。IPF的发病机制尚不清楚。目前,尚无有效的治疗方法治愈IPF。确定IPF发病机制的分子途径对于开发新的IPF靶向治疗方法至关重要。粘着斑激酶(FAK)是一种酪氨酸激酶,在细胞迁移、增殖/存活和肌成纤维细胞分化过程中发挥重要作用。FAK相关非激酶(FRNK)是FAK介导的细胞迁移和肌成纤维细胞分化的内源性抑制因子。为探讨FRANK在IPF患者肺纤维化发生发展中的作用,我们提出了两个特定的目标。这项提案将研究frnk和FAK的表达,以及FAK及其下游介体的激活。拟议研究的结果将分析与IPF患者肺纤维化严重程度的相关性。拟议的研究结果将为FRANK在肺纤维化发展中的作用提供新的见解,并作为进一步机制研究的基础。公共卫生相关性:拟议的研究将提供有关FAK相关的非激酶在人类肺纤维化发展中的作用的新见解。(摘要结束)
英文摘要
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder resulting in progressive respiratory insufficiency and lung fibrosis with fatal outcome. The pathogenesis of IPF remains unclear. Currently, there is no effective therapy to cure IPF. Characterization of molecular pathways involved in the pathogenesis of IPF is essential to develop novel targeted therapeutic approaches for IPF patients. Focal adhesion kinase (FAK) is a tyrosine kinase and plays a critical role in cell migration, proliferation/survive, and myofibroblast differentiation. FAK-related non-kinase (FRNK) is an endogenous inhibitor of FAK-mediated cell migration and myofibroblast differentiation. To investigate the role of FRNK in the development of lung fibrosis in IPF patients, two specific aims are proposed. This proposal will examine the FRNK and FAK expression, and the activation of FAK and downstream mediators. The findings from the proposed studies will be analyzed for the correlation with the severity of lung fibrosis in IPF patients. The findings of the proposed studies will provide new insights regarding the role of FRNK in the development of lung fibrosis, and serve as the basis for further mechanistic studies. PUBLIC HEALTH RELEVANCE: The proposed studies will provide new insights regarding the role of FAK-related Non- kinase in the development of pulmonary fibrosis in human. (End of Abstract)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Impaired FRNK in IPF
The Impaired FRNK in IPF
The Impaired FRNK in IPF
Molecular Mechanism of Lung Barrier Dysfunction
海外基金